Japanese Perspectives on the Reproductive and Developmental Toxicity Evaluation of Pharmaceuticals

Abstract

The current Japanese guidelines for reproductive and developmental toxicity studies of drugs stress the need for examination of the effects of drugs on the behavior and fertility of the offspring. In 1986, the Ministry of Health and Welfare initiated a review of all current toxicity test guidelines, one of the objectives of the review being to increase the international harmonization of such guidelines. The final report of the Reproduction Study Subgroup was officially released on September 11, 1989. A summary of the conclusions of the study subgroup follows: To attain international conformity of guidelines requires scientific discussion among international organizations, but an early solution will be difficult. A more practical way is to accept studies performed in conformity with other guidelines if the applicant submits a document demonstrating that the same degree of safety for human reproduction and development required by the Japanese guidelines can be judged from the characteristics and clinical indications of the drug., Positive discussion is also necessary with other countries to agree on conditions under which studies performed according to the Japanese guidelines will be acceptable to such countries. In addition, the current status of behavioral teratology tests in Japan surveyed by the Behavioral Teratology Meeting, Japanese Teratology Society is presented.

References

Kida, M.

(1987). Thalidomide Embryopathy in Japan. Tokyo: Kodansha.

2. U.S. Food And Drug Administration (1966). Guidelines for Reproduction Studies for Safety Evaluation of Drugs for Human Use.

3. Ministry Of Health And Welfare, Japan. (1975). On Studies of the Effects of Drugs on Reproduction. Notification No. 529 of the Pharmaceutical Affairs Bureau, Ministry of Health and Welfare. March 31.

4. Ministry Of Health And Welfare, Japan. (1984). Information on the Guidelines of Toxicity Studies Required for Applications for Approval to Manufacture (Import) Drugs. Notification No. 118 of the Pharmaceutical Affairs Bureau, Ministry of Health and Welfare. February 15.

5. World Health Organization. (1984). Principles for evaluating health risks to progeny associated with exposure to chemicals during pregnancy. Environ. Health Crit. 30.

Baeder, C.

Wickramaratne, G.A.S.

Hummler, H.

Merkle, J.

Schön, H.

, and

Tuchmann-Duplessis, H.

(1985). Identification and assessment of the effects of chemicals on reproduction and development (reproductive toxicology). Food Chem. Toxicol. 23, 377–388.

Christian, M.S.

, and

Hoberman, A. M.

(1985). Current in vivo reproductive toxicity and teratology methods. In:

Homburger, F.

, ed. Safety Evaluation and Regulation of Chemicals 2. Second International Conference, Cambridge, Ma, 1983. Basel: Karger. pp. 78–88

U.S. Environmental Protection Agency

(1986). Guidelines for the health assessment of suspect developmental toxicants. Fed. Reg. 51, 34028–34040.

Kimmel, G.L.

Kimmel, C.A.

, and

Francis, E. Z.

(1987). Implication of the consensus workshop on the evaluation of maternal and developmental toxicity. Teratogen. Carcinogen. Mutagen. 7, 329–338.

10.

Neubert, T.

Chahould, I.

Platzek, T.

, and

Meister, R.

(1987). Principles and problems in assessing prenatal toxicity. Arch. Toxicol. 60, 238–245. 11.

11.

Schardein, J.L.

(1988). Teratologic testing: status and issues after two decades of evolution. Rev. Environ. Contam. Toxicol. 102, 1–78.

12.

12. Nordic Council On Medicine. (1983). Drug Application. Nordic Guidelines, Nln Publication No. 12.

13.

13. European Communities. (1983). Concerning tests relating to the placing on the market of proprietary medicinal products. Off. J. Eur. Commun. No. L332, 11-32.

14.

Tanimura, T.

(1985). Guidelines for developmental toxicity testing of chemicals in Japan. Neurobehav. Toxicol. Teratol. 7, 647–652.

15.

Wilson, J.G.

(1973). Environment and Birth Defects. New York: Academic Press.

16.

Tanimura, T.

(1984). Prospects of the reproductive toxicology with special reference to the developmental hazards due to the treatment at the stage from prefertilization to implantation. Cong. Anom. 24, 319–328.

17.

Adams, P.M.

Fanini, D.

, and

Legator, M. S.

(1987). Neurobehavioral effects of paternal drug exposure on the development of the offspring. In:

Fujii, T.

and

Adams, P.M.

, eds. Functional Teratogenesis. Tokyo: Teikyo University Press, pp. 147–156

18.

18. World Health Organization. (1986). Guidelines of the Assessment of Drugs and Other Chemicals for Behavioural Teratogenicity (Draft). Copenhagen: World Health Organization, Regional Office for Europe.

19.

Kimmel, C.A.

Buelke-Sam, J.

, and

Adams, J.

(1985). Collaborative Behavioral Teratology Study: implications, current applications and future directions. Neurobehav. Toxicol. Teratol. 7, 669–673.

20.

U.S. Environmental Protection Agency.

(1988). Diethylene glycol butyl ether and diethylene glycol butyl ether acetate; test standards and requirement. Fed. Reg. 53, 5932–5953.

21.

Riley, E.P.

, and

Vorhees, C. V.

(1986). Handbook of Behavioral Teratology. New York: Plenum Press.

22.

Tanimura, T.

(1983). The Behavioral Teratology Meeting, a satellite meeting to the Annual Meeting of the Japanese Teratology Society. Cong. Anom. 23, 127–130.

23.

Tanimura, T.

(1986). Collaborative studies on behavioral teratology in Japan. Neurotoxicology 7, 35–46.

24.

Butcher, R.E.

Vorhess, C.V.

, and

Kimmel, C. A.

(1972). Learning impairment from maternal salicyiate treatment in rats. Nature (New Biology) 236, 211–212.